How can pharma help the NHS capitalise on its data?
Sue Thomas, Paul Midgley and Steve How, of Wilmington Healthcare, explain how pharma can work with the NHS to transform services
NHS organisations cannot make significant improvements to their services without a detailed knowledge and understanding of how they are currently performing, and where problems and inefficiencies exist.
However, although industries ranging from retail to insurance have been successfully harnessing big data for years to improve products and services, the NHS has struggled to capitalise on complex data.
For example, critical data on admissions, outpatient appointments and A&E attendances at NHS hospitals have been available via Public Health Observatories and other sources for some time, and complemented by data on specific diseases in recent years.
However, commissioners have struggled to access it in order to plan and commission new pathways, and have been further hampered by the fact that primary and secondary care datasets have not been linked. Where they are taking advantage of data, it is likely to be in priority disease areas only.
Consequently, many NHS organisations do not know the full extent of how patients are utilising their services and why. Similarly, they do not know where improvements and cost-savings could be made by, for example, treating recurrent infections in patients suffering from diseases such as multiple sclerosis at primary care level to keep them out of hospital. These issues, combined with time pressures on staff, mean that NHS organisations cannot benchmark their services against other parts of the health service either.
How can pharma help?
With the NHS struggling to afford to capture, procure and analyse its own data, there is a huge opportunity for pharma to help shape the way that NHS services are delivered by gathering this data themselves, analysing it and sharing the findings with CCGs, NHS trusts and new emerging organisations.
At Wilmington Healthcare, we draw on a variety of sources from NHS Digital, such as Hospital Episode Statistics (HES), alongside interviews with stakeholders, such as vanguards, CCGs and patients, to gather insight on trends, gaps or inefficiencies in patient care in a variety of priority and non-priority disease areas.
These insights can be used to highlight the burden of disease; identify variations in patient outcomes and provide evidence for change in therapeutic areas. They can also help the NHS gain a clear understanding of the impact that pathways have on patients’ experiences and outcomes, and highlight areas of best practice and opportunities for improved efficiencies.
Thanks to advanced data mining capabilities, information can be analysed at a granular level to give a local and regional picture, as well as a national one. This also means that the actual causes for hospital admissions can be highlighted and followed over time, rather than simply shown in ‘headline numbers’.
Where there is a clear benefit to health and social care outcomes, such data can be used by pharma to engage peer-to-peer with trusts/CCGs and inform an initial ‘case for change’ for a particular patient pathway, which can then lead to a detailed business case developed by a multi-disciplinary group.
For example, one pharma company has supported development of a disease insight report in partnership with a charity to highlight a cross-sectional analysis of hospital data. This revealed reasons for emergency hospital admissions – which can now be tackled at a national level but the data also highlighted that the majority of elective admissions (which were thought to be high) were in actual fact due to an uptake of disease-modifying therapy.
Another pharma company has supported development of an England-wide report to be used by an All Party Parliamentary Group (APPG). These reports have been used effectively to influence service design, health policy and improve patient outcomes.
As new data sources become available following the amalgamation of health and social care within STPs, Wilmington Healthcare will work with pharma and the NHS to follow wider and more complex patient journeys that may, for example, go from a GP to community services to hospital and then social care.
In conclusion, there is a real opportunity for pharma to help shape NHS services by gathering and analysing data around relevant disease areas and identifying where it can help to improve patient outcomes and save money. Having access to this kind of data can give pharma the edge by enabling it to approach a cash-strapped NHS with solutions rather than problems.
Ends
Sue Thomas is CEO of the Commissioning Excellence Directorate; Paul Midgley is Director of NHS insight; Steve How is Business Development Director, all at Wilmington Healthcare. For information on Wilmington Healthcare, log on to www.wilmingtonhealthcare.com
This content was provided by Wilmington Healthcare
Company Details
Latest Content from Wilmington Healthcare
New local NHS models help to deliver integrated care
Steve How, of Wilmington Healthcare, explains how health and social care groups are uniting within ‘neighbourhoods’
Wilmington Healthcare adds innovative new features to its digital learning platform for pharma and medtech
Healthcare intelligence provider Wilmington Healthcare has introduced a host of new features to its unique digital learning platform, which enables pharma and medtech sales staff to keep abreast of NHS...
HSJ Awards Finalists Announced
2018 HSJ Awards Finalists Announced.
HSJ Partnership Awards will showcase pharma’s inspirational joint working projects with the NHS
Health Service Journal (HSJ), the news and information service for all healthcare leaders working in, for, or with the NHS, has expanded and enhanced its Partnership Awards for 2019.
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change
Wilmington Healthcare wins first client for new NHS transformation tracker
Product helps pharma identify opportunities and tailor solutions to a changing NHS
Wilmington Healthcare appoints new Commercial Director
Healthcare intelligence provider Wilmington Healthcare, which incorporates HSJ, Binley’s, OnMedica and Wellards, has appointed Sue Plant as Commercial Director for MedTech.
How can pharma support NHS service change?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, find some answers in NHS England guidance for commissioners
Sir Bruce Keogh is appointed chair of judges for HSJ Awards
Sir Bruce Keogh, the former National Medical Director for NHS England, will chair the judges’ panel for the 37th annual HSJ Awards – the world’s largest healthcare awards programme.
How will new data protection law affect pharma?
Sarah Eglington, of Wilmington Healthcare, explores how GDPR will change pharma’s relationship with healthcare professionals